{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PWS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":30.75,"timestamp":1744736693677,"preClose":30.72,"halted":0,"volume":3388,"delay":0,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Trading","change":0.03,"latestTime":"04-15 13:08:13 EDT","open":30.7499,"high":30.75,"low":30.7101,"amount":104156.243884,"amplitude":0.001299,"askPrice":30.75,"askSize":500,"bidPrice":30.71,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1744747200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"BATS","adjPreClose":30.72,"sharesOutstanding":750000,"nav":30.74,"aum":23055000,"bidAskSpread":0.001185,"volumeRatio":0.134179},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.134179,"shares":750000,"dividePrice":0.43469,"high":30.75,"amplitude":0.001299,"preClose":30.72,"low":30.7101,"week52Low":27.39,"pbRate":"--","week52High":32.64,"institutionHeld":0,"latestPrice":30.75,"eps":0,"divideRate":0.014136,"volume":3388,"delay":0,"ttmEps":0,"open":30.7499,"prevYearClose":30.4061,"prevWeekClose":30.72,"prevMonthClose":30.818,"prevQuarterClose":30.818,"fiveDayClose":30.72,"twentyDayClose":30.7884,"sixtyDayClose":31.5051},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PWS\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527538461","title":"Soleno Therapeutics Announces VYKAT(TM) XR Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2527538461","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527538461?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:00","pubTimestamp":1744628400,"startTime":"0","endTime":"0","summary":"First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April  14, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/14/3060770/0/en/Soleno-Therapeutics-Announces-VYKAT-TM-XR-Launch.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","PWS","TM","BK4585","BK4139","BK4555","BK4604","BK4588","SLNO","BK4099"],"gpt_icon":0},{"id":"2524097441","title":"Press Release: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2524097441","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524097441?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:10","pubTimestamp":1743451800,"startTime":"0","endTime":"0","summary":"-- Lead candidate ARD-101 demonstrated clinical activity and was generally. well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome ,with meaningful reductions in hyperphagia (up to a 16-point HQ-CT. reduction, with an average reduction of approximately 8 points among. subjects that followed trial protocol) observed during the 28-day dosing. -- DEXA scans analysis from the PWS Phase 2 trial data measuring body. composition indicated a trend toward decreased body fat (approximately. -- Aardvark bolstered its cash runway through the successful completion of. SAN DIEGO, March 31, 2025  -- Aardvark Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December 31, 2024, and provided business highlights.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","AARD","IPO"],"gpt_icon":0},{"id":"2522653140","title":"Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522653140","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522653140?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer, to be presented at AUA 2025 in April. Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome. Cash balance of $44.8 million as of December 31 2024. Management hosting conference call and webcast today at 4:30 PM ET. “An important dimension of our strategic options exploration has been the development of a portfolio of programs with near-term value drivers that can address under-served markets. While we maintain deep expertise in diseases of the central nervous system, as we evaluate strategic opportunities, the broad drug development expertise of our Team provides flexibility to be opportunistic,” commented Maged Shenouda, CFO of Relmada. “With a $44.8 million cash balance, as of December 31, 2024, and clean balance sheet, we begin the year with solid financial strength.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-reports-fourth-quarter-200500181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RLMD","BK4081","BK4563","BK4139","PAM","BK4532","ALLO","LENZ","CDC","BK4007","PWS","BK4505","TS","BK4179","IE00B1B80R65.USD"],"gpt_icon":0},{"id":"2522003463","title":"SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522003463","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522003463?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:46","pubTimestamp":1743079560,"startTime":"0","endTime":"0","summary":"Shares of Soleno TherapeuticsSLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR extended-release tablets for treating hyperphagia in adults and children aged four years and older with Prader-Willi syndrome . The company expects to launch the drug in the United States in April 2025.Soleno’s Vykat XR, previously referred to as DCCR, is an innovative, once-daily, proprietary extended-release dosage form that contains diazoxide choline, the crystalline salt form of diazoxide. Although not approved for treating PWS, the parent molecule, diazoxide, treats a few rare diseases in neonates, infants, children and adults.Per the PWS Association USA, approximately one in every 15,000 newborns suffers from this rare genetic disorder. The most common symptom of PWS is hyperphagia, an abnormally increased appetite for food, often leading to excessive eating, which takes a serious toll on the quality of life of patients suffering from it. In the long term, hyperp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/slno-stock-rallies-fda-approval-124600150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","LU2065171311.SGD","BAYRY","BK4007","PWS","LU2065170008.USD","LU1559883803.SGD","BK4532","ACAD","LU2065171402.SGD","BK4139","CORT","SLNO","LU2065169927.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2025-03-06","symbol":"PWS","amount":0.059681,"announcedDate":"2025-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-06","defaultRemindTime":1741271400000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-03-06","currency":"USD","dateTimestamp":1741237200000,"payDate":"2025-03-12"},{"date":"2024-12-27","symbol":"PWS","amount":0.206094,"announcedDate":"2024-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-27","defaultRemindTime":1735309800000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-02","payableDate":"2024-12-27","currency":"USD","dateTimestamp":1735275600000,"payDate":"2025-01-02"},{"date":"2024-09-26","symbol":"PWS","amount":0.121716,"announcedDate":"2024-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-26","defaultRemindTime":1727357400000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-02","payableDate":"2024-09-26","currency":"USD","dateTimestamp":1727323200000,"payDate":"2024-10-02"},{"date":"2024-06-27","symbol":"PWS","amount":0.047202,"announcedDate":"2024-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-27","defaultRemindTime":1719495000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-03","payableDate":"2024-06-27","currency":"USD","dateTimestamp":1719460800000,"payDate":"2024-07-03"},{"date":"2024-03-21","symbol":"PWS","amount":0.030854,"announcedDate":"2024-03-20","type":"dividend","market":"US","newRecordDate":"2024-03-22","name":"Pacer WealthShield ETF","recordDate":"2024-03-27","payableDate":"2024-03-22","currency":"USD","dateTimestamp":1710993600000,"payDate":"2024-03-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{}}}